, Tracking Stock Market Picks
Enter Symbol:
Rating: IPXL

Impax Laboratories, Inc. (NASDAQ: IPXL) downgraded to Neutral by JP Morgan

Wednesday,  Jan 6, 2016  10:25 AM ET by Betsy O'Brien Harrison

JP Morgan downgraded Impax Laboratories, Inc. (NASDAQ: IPXL) to Neutral. Previously
JP Morgan downgraded to Impax Laboratories, Inc. (NASDAQ: IPXL) to Overweight with price target $18 on 01/04/2010, when the stock price was $13.92.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy